RP
VTAE

Rowlandmiller & Partners’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Rowlandmiller & Partners’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,487
Closed -$457K – 126
2015
Q4 		$457K Buy
+4,487
New +$61.7K 0.23% 67
2015
Q3 		– Sell
-4,358
Closed -$466K – 127
2015
Q2 		$466K Buy
+4,358
New +$59.2K 0.23% 69

Other funds holding VTAE

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rowlandmiller & Partners's VTAE Position: Q1 2016 in Review

Rowlandmiller & Partners sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q1 2016, closing a stake of 4,487 shares — an estimated $457K sold.

Rowlandmiller & Partners first reported a position in VTAE in Q2 2015 and held it in 2 quarters. The position peaked at $466K in Q2 2015. 78 funds tracked by Wall St. Rank hold VTAE as of Q1 2016.

  • Rowlandmiller & Partners reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q1 2016 after selling out during the quarter.
  • Rowlandmiller & Partners sold 4,487 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q1 2016, an estimated $457K.
  • Rowlandmiller & Partners first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q2 2015 and held it in 2 quarters.
  • Rowlandmiller & Partners's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $466K in Q2 2015.
  • 78 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q1 2016.

Based on Rowlandmiller & Partners's 13F filing for Q1 2016, filed 11 Apr 2016.